8.1 Neonatal Hyperbilirubinemia & Jaundice Management

8.1 Neonatal Hyperbilirubinemia & Jaundice Management

Neonatal jaundice, or hyperbilirubinemia, is one of the most common clinical conditions encountered in the neonatal intensive care unit (NICU), affecting approximately 60% of term and 80% of preterm infants during the first week of life. It is characterized by the yellow discoloration of the skin, sclera, and mucous membranes caused by the deposition of unconjugated or conjugated bilirubin in these tissues. Understanding the metabolic pathways, distinguishing between physiologic and pathologic jaundice, and executing timely, evidence-based management are crucial responsibilities for the RNC-NIC nurse to prevent irreversible neurological damage.

Bilirubin Metabolism Pathway

Bilirubin is a product of heme catabolism. The physiological pathway proceeds as follows:

1. Red Blood Cell Breakdown: Senescent red blood cells are phagocytosed by mononuclear phagocytes in the spleen and liver. Hemoglobin is broken down into heme and globin.
2. Heme Catabolism: Heme is converted into biliverdin by the enzyme heme oxygenase, releasing carbon monoxide (exhaled) and iron (reutilized) in the process.
3. Biliverdin Reduction: Biliverdin is reduced to unconjugated (indirect) bilirubin by biliverdin reductase. Unconjugated bilirubin (UCB) is lipophilic, hydrophobic, and virtually insoluble in water.
4. Albumin Binding: In the bloodstream, UCB binds reversibly to albumin. This binding is essential because free UCB (not bound to albumin) can cross the blood-brain barrier and cause neurotoxicity.
5. Hepatic Uptake and Conjugation: In the liver, UCB is detached from albumin and transported into hepatocytes by ligandins (Y and Z proteins). The enzyme uridine diphosphate glucuronosyltransferase (UGT1A1) conjugates UCB with glucuronic acid to form water-soluble conjugated (direct) bilirubin.
6. Excretion: Conjugated bilirubin is excreted into the bile and enters the small intestine. In adults, gut flora reduce it to urobilinogen for fecal or urinary excretion.
7. Enterohepatic Circulation: Neonates have a sterile gut and high concentrations of the enzyme beta-glucuronidase in the intestinal mucosa. This enzyme deconjugates direct bilirubin back into lipophilic unconjugated bilirubin, which is reabsorbed through the intestinal wall into the portal circulation, returning to the liver.

---

Physiologic vs. Pathologic Jaundice

Distinguishing between physiologic and pathologic jaundice is critical for preventing Bilirubin-Induced Neurologic Dysfunction (BIND) and its chronic form, kernicterus.

Comparison of Jaundice Types

Etiology of Pathologic Jaundice

Pathologic unconjugated hyperbilirubinemia is categorized into hemolytic and non-hemolytic causes:

• Isoimmune Hemolytic Disease: ABO incompatibility (typically mother is O, baby is A or B, and the Direct Antiglobulin Test [DAT/Coombs] is positive) or Rh incompatibility (Rh-negative mother, Rh-positive baby; causes severe anemia and hydrops fetalis if not managed with antenatal Rho(D) immune globulin).
• Erythrocyte Defects: Glucose-6-phosphate dehydrogenase (G6PD) deficiency (an X-linked disorder that causes hemolysis under oxidative stress), hereditary spherocytosis.
• Extravascular Hemorrhage: Cephalohematoma, subgaleal hemorrhage, or significant cutaneous bruising, which increases the bilirubin load as red blood cells break down.
• Polycythemia: An elevated hematocrit (>65%) provides a larger volume of red blood cells for breakdown.
• Lactation Failure Jaundice: Early-onset (first 2–4 days) jaundice caused by poor milk intake, leading to dehydration, weight loss, delayed passage of meconium, and a subsequent increase in enterohepatic circulation.
• Breast Milk Jaundice: Late-onset (peaking in the second week of life) jaundice associated with factors in breast milk (e.g., beta-glucuronidase, free fatty acids) that promote enterohepatic reabsorption.

Conjugated (direct) hyperbilirubinemia is always pathologic and indicates hepatobiliary disease. The clinical signs include acholic (pale, clay-colored) stools, dark tea-colored urine, and hepatomegaly. Common causes include biliary atresia (requiring surgical intervention via the Kasai procedure before 60 days of life), neonatal hepatitis, TPN-associated cholestasis, and metabolic disorders (e.g., galactosemia).

---

Screening and Nomogram Risk Stratification

All infants should be screened for jaundice using transcutaneous bilirubin (TcB) or total serum bilirubin (TSB) measurements prior to discharge, or immediately if jaundice is visible in the first 24 hours of life.

The Bhutani Nomogram plots hour-specific TSB values for infants \ge35 weeks gestation to determine the risk of developing severe hyperbilirubinemia. The nomogram is divided into risk zones:

• High-Risk Zone: >95th percentile. Requires immediate assessment and initiation of phototherapy.
• High-Intermediate Risk Zone: 75th to 95th percentile. Requires close follow-up and consideration of therapy depending on risk factors.
• Low-Intermediate Risk Zone: 40th to 75th percentile.
• Low-Risk Zone: <40th percentile.

Clinical Risk Factors Lowering the Treatment Threshold

When determining treatment thresholds on the American Academy of Pediatrics (AAP) phototherapy guidelines, the presence of the following risk factors lowers the bilirubin level at which phototherapy or exchange transfusion is indicated:

• Gestational age <38 weeks (risk increases with decreasing gestational age due to blood-brain barrier immaturity)
• Isoimmune hemolytic disease (ABO or Rh incompatibility)
• G6PD deficiency
• Sepsis or clinical instability
• Acidosis (disrupts bilirubin-albumin binding)
• Asphyxia or therapeutic hypothermia
• Significant lethargy
• Serum albumin < 3.0 g/dL (reduces binding capacity, increasing free bilirubin)

---

Phototherapy Management

Phototherapy is the primary therapeutic intervention for unconjugated hyperbilirubinemia.

Mechanism of Action

Phototherapy does not conjugate bilirubin. Instead, it delivers light in the blue-green spectrum (wavelengths of 430–490 nm, with peak efficacy at 460 nm) at an irradiance of \ge30 \muW/cm²/nm. The light penetrates the subcutaneous tissue and alters unconjugated bilirubin via two photochemical reactions:

1. Photoisomerization: Converts UCB into a structural isomer called lumirubin. This reaction is irreversible. Lumirubin is highly water-soluble and is rapidly excreted in the urine and bile without requiring hepatic conjugation.
2. Configurational Isomerization: Converts UCB into less toxic configurational isomers. This reaction is reversible, and the isomers are excreted in the bile.

Nursing Interventions and Safety Measures

• Retinal Protection: Opaque eye patches must be securely placed over the infant's eyes to protect the retina from high-intensity light. The nurse must verify proper placement every 4 hours, ensuring the patch does not slip and obstruct the nares. Check the eyes for drainage, infection, or corneal irritation during feedings.
• Skin Exposure: Maximize exposed skin surface area. The infant should wear only a diaper. Turn the infant regularly to expose different skin surfaces (though continuous supine positioning is acceptable under LED blankets).
• Thermoregulation: Monitor axillary temperature every 3–4 hours. Servo-controlled incubators or radiant warmers may be necessary because the infant is unclothed and at risk for hypothermia or hyperthermia from the lights.
• Hydration and Fluid Balance: Monitor fluid intake and output. Insensible water loss increases by 10–20% in term infants and up to 50% in preterm infants under phototherapy. Promote frequent enteral feedings (every 2–3 hours) to stimulate peristalsis and stooling, which minimizes enterohepatic circulation. IV fluids are reserved for infants with significant dehydration or feeding intolerance.
• Bronze Baby Syndrome: If phototherapy is initiated in an infant with elevated conjugated bilirubin, the skin, serum, and urine can develop a dark, grayish-brown discoloration due to the accumulation of copper porphyrins. Discontinue phototherapy and investigate the underlying cholestatic pathology.

---

Exchange Transfusion

Exchange transfusion is a high-risk, emergency procedure indicated when TSB levels exceed the exchange threshold despite intensive phototherapy, or if the infant exhibits signs of Acute Bilirubin Encephalopathy (ABE).

Clinical Indicators of ABE

• Early Signs: Lethargy, hypotonia, poor suck, and a high-pitched cry.
• Intermediate Signs: Hypertonia, irritability, retrocollis (arching of the neck), and opisthotonos (arching of the back).
• Advanced Signs: Shrill cry, seizures, apnea, fever, and coma. Without treatment, this progresses to chronic kernicterus (athetoid cerebral palsy, sensorineural hearing loss, enamel dysplasia, and upward gaze palsy).

Procedure Details

A Double-Volume Exchange Transfusion (DVET) replaces approximately 160–180 mL/kg of the infant's circulating blood volume (normal neonatal blood volume is ~80–90 mL/kg).

• Blood Product: Typically uses reconstituted whole blood consisting of O-negative packed red blood cells suspended in AB-negative fresh frozen plasma, crossmatched against maternal and infant serum. The blood should be fresh (<5 days old) to avoid high potassium levels.
• Access: Performed via umbilical venous and arterial catheters.
• Method: Blood is withdrawn and infused in small aliquots (typically 5–10 mL/kg per cycle) over 1.5 to 2 hours.

Nursing Care and Potential Complications

The nurse must continuously monitor vital signs, electrocardiogram (ECG), and catheter patency. Complications of exchange transfusion are severe and include:

• Hypocalcemia: Citrate anticoagulant in the donor blood binds to the infant's ionized calcium. The nurse must monitor for jitteriness, tachycardia, or a prolonged QTc interval on the ECG. Administer calcium gluconate if indicated.
• Hyperkalemia: Lysis of red blood cells in stored blood can release potassium. Check post-procedure electrolytes.
• Thrombocytopenia: Donor blood lacks functional platelets, leading to dilutional thrombocytopenia.
• Metabolic Acidosis and Alkalosis: Acidosis may occur during the procedure due to the donor blood's preservative, followed by metabolic alkalosis as citrate is metabolized to bicarbonate.
• Necrotizing Enterocolitis (NEC): Caused by mesenteric ischemia during volume shifts. Feedings should be held for at least 24 hours post-procedure.
• Vascular and Cardiac Complications: Portal vein thrombosis, air embolism, vasospasm, and arrhythmias.

Exam Traps

• TcB after Phototherapy: Transcutaneous bilirubin (TcB) measurements are not accurate once phototherapy has begun because the light bleaches the skin. Decisions to escalate or discontinue therapy must be based on total serum bilirubin (TSB) levels.
• Direct Bilirubin Treatment: Never use phototherapy to treat isolated conjugated (direct) hyperbilirubinemia. It has no therapeutic effect and carries a risk of Bronze Baby Syndrome.